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Advances in optics technology, synthetic photochem-
istry, and the science of photobiology make it possible to 
think beyond phototherapy and photochemotherapy 
which is dependent on direct photochemical alteration 
of metabolites or direct phototoxic insult to cells. This 
report discusses another gender of photomedicine ther-
apy which includes in vivo photoactivation of medicines, 
photon-dependent drug delivery, and manipulation of 
host and exposure source to maximize therapeutic index. 
These therapeutic manipulations are made possible be-
cause the skin is highly overperfused and because non-
ionizing electromagnetic radiation that enters skin and 
blood has adequate photon energy to cause electronic 
excitation. Radiation of 320-800 nm is not very directly 
phototoxic, is absorbed by a variety of relatively non-
toxic photolabile molecules and has an internal dosi-
metric depth profile. This radiation can therefore be 
used to activate, deactivate, bind, release or biotrans-
form medications in vivo in skin or other organs. The 
photochemist, synthetic chemist and photobiologist can 
collaborate to significantly increase therapeutic possi-
bilities. 
Visible light can be used to prevent bilirubin encephalopathy 
in jaundiced newborns and to remove cuta neous hemangiomas. 
Ultraviolet radiation can be used to treat a variety of common 
a nd uncommon skin diseases and often changes disabling dis-
ease to a manageable problem, Yet it is likely that the potential 
for th erapeutic use of ultraviolet and visible radiation is much 
greater than presently realized , Present forms of phototherapy 
depend on direct effects of photons on abnormal cells or on 
metabolites present in excessive amounts , The I1hoton itself is 
th e intended pharmacologic or therapeutic agent (see Table). 
The genesis of these treatments was the observation of thera-
peutic effects of sunlight and the mode of development has 
been mostly trial and error utilizing available exposure sources. 
Direct in vivo photochemical cell injury (phototoxicity) is 
also the most likely mecha nism for photochemotherapy. By 
supplying an exogenous chromophore that is somewhat site· 
specific and leads to a specific pho tochemistry, this form of 
treatment potentially increases target selectivity or t reatment 
efficacy. Photochemotherapy combines the ease a nd uniform 
distribution of systemic drug administration wi th selective spa-
tial effects achieved by radiation . In the last decade this form 
of therapy has been successfully reduced to practice in a some-
what rational and systemic way utilizing modern lamp design , 
radiometry and careful dosimetry and has achieved limited 
success in the form of oral psoralen photochemotherapy. How-
ever, the concept of photochemotherapy is most likely more 
important than any present application. 
Advances in optics technology and the science of photobiol-
ogy make it possible to think beyond therapy which is depen-
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dent on direct photochemical alteration of metabolites or direct 
phototoxic insul t to cells. This report discusses another gener-
ation of photomedicine t herapy which includes in vivo pho-
toactivation of medicines, photon-dependent drug delivery and 
creative manipulation of host a nd exposure source to maximize 
therapeutic index. We also summarize some of the photobiol-
ogic and biologic proper t ies of skin and blood which make such 
treatmen ts possible a nd examine some of the variables available 
for therapeutic manipulation. 
Knowledge of the ways in which rad iation affects biological 
matter ult imately permits these t herapeutic manipulations. 
Specific biomolecules within cells can be altered in precise ways 
without the t issue being entered by chemicals, physically in-
vaded or disrupted. For these considerations radiation can be 
imagined as energy in tra nsit; electromagnetic radiation (EMR) 
is energy that can be t ransmi tted t hrough a vacuum. Energy 
can be emitted from a n excited species (source) and subse-
quently invested in a nother molecule a few nanometers or 
hundreds of millions of miles away. The source may be an 
electrically excited gaseous arc; the a bsorbing molecule may be 
a chromophore i.n a living skin cell . EMR has the properties of 
both waves and particles. Many of the interactions of electro-
magnetic radiation with matter ar e best described by wave 
properties. Refraction, diffraction, polarization, and classical 
scattering are good examples. The wave character is best de-
scribed as transverse waves of rapidly alternating electric and 
magnetic fields which are perpendicular to each and to the 
di.rection of propagation, Any specific EMR may be described 
by either the frequency (number of wave oscillations per sec-
ond) or the wavelength (distance travelled pel' oscillation) . 
Because all EMR is propagated at the same velocity in a 
vacuum, frequency and wavelength have a precise inverse re-
lationship. 
On the other hand, cer tain properties of EMR are best 
understood by considering discrete bundles or particles of finite 
energy (photons or quanta). The energy of a single photon is 
proportional to its frequency, and therefore is inversely propor-
t ional to wavelength , When a photon is absorbed, all of the 
photon's energy is transferred to the absorbing molecule · and 
the photon no longer exists. Absorption is a precise phenome-
non which depends upon the "aU owed" electronic states and 
transitions within the absorber and how these match with the 
energy of the photon. Absorption must take place in order for 
photochemistry to occur (Grotthus-Draper law) , because the 
photon must supply activation energy for these reactions. 
For some finite period of t ime, the excess energy presented 
to a m olecule by a photon resul ts in an "excited" state of the 
molecule. The mode of this excitation depends upon the amount 
of energy invested (photon energy). At very high photon ener-
gies, e,g., x-rays, interaction may cause electrons to be ejected 
from the absorbing molecule, i.e., photo-ionization of the mol-
ecule, Infrared photons (longer wavelength, lower energy pel' 
photon) typically excite ro ta tional and vibrational states resul t-
ing in chan ges most often recorded as heat. Absorption of 
visible and ul traviolet radiation leads to electronic excitations-
changes in the orbital shells that the m olecule's 01' atom's 
electrons occupy, actually creating an "electronic isomer" of 
the unexcited ground state molecule. 
The excited molecule may dissipate its excess energy as heat 
or re-emit it as E MR (fluorescence or phosphorescence). The 
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Therapy with optical radiation (UV, VIS, N JR) 
Mechanism 
Direct E ffects (Phototherapy) 
Selective photo toxicity 
P hotochemistry of metabolites 




P hoton activation or inactivation 
of medicines 
Photolab ile Li posome carriei·s 
Examples 
(Disease Treated) 
Psorias is (UVB) 
{
Hyperbilirubinemia 
(blue ligh t) 
Uremic Pruritus (UVB) 




excited molecule may be structW'ally altered or cleaved, or it 
may react chemically with other molecules. In biological sys-
tems the photochemical alterations may eventually result in 
changes in cell function, mutation, death or other responses. 
Membranes, enzymes, DNA, RNA and other biomolecules may 
be altered and macromolecular synthesis temporarily de-
creased. Repail' enzym es attempt to remove photoproducts 
from DNA. Photoproducts and media tors are released from cell 
membranes, Iysosom es, and other organelles. Unlike either 
higher quantum energy (x-rays, gamma rays) or lower quantum 
energy (far infrared, microwaves), the opt ical portion (ultravi-
olet, visible, near infrared) of t he spectrum can produce a large 
variety of highly specific biologic effects. This is because the 
quantum energy of UV and visible photons corresponds to the 
activation of specific molecules or chromophores, usually re-
sult ing in specific alterations of those a bsorbing centers. Thus, 
it is possible to "drive" a given photochemical reaction to the 
relative exclusion of others by supplying specifi c chromophores 
and choosing the right wavelengths. The s'pecificity with which 
photochemical reactions can occur is similar to that for phar-
macologic agents or enzym es, yet we are only beginning to 
utilize this potential. 
If radiation induces sufficient cell injW'y, whole organs react. 
For example.,in the skin, after a latent period of several hours, 
t he classic signs of inflammation appear. Rubor, tumor, calor, 
dolor last for hoW's to days and are followed by epidermal 
hyperproliferation and hyperpigmentation. These responses 
most often depend on the energy per photon (wavelength) and 
t he number of photons absorbed. The number of photons 
present at each wavelength depends on the- particular properties 
of the radiation source and the operating conditions. The inter-
nal spectral dosimetric profile depends on the optical properties 
of the .tissue. T he optical properties of skin and blood should 
allow t he use of photons to release, activate or deactivate 
chemicals 0 1' medications at specific sites and depths within 
t issue. This can be achieved in a variety of ways, some examples 
of wI!ich are given below. 
AMPLIFICATION OF PHOTON SIGNALS 
Within cells or orga nisms photons may act as signals; t heir 
effects can , be amplified in a variety of ways that magnify 
photobiologic responses. Naturally occurring systems of ampli-
fi cation initiated by photochemical reactions include gene 
repression or depl'ession , enzyme activa t ion or inactivation, 
control of hormones (release, binding, biotransformation), and 
control of membrane properties [I). Photons may affect en-
zymes by a variety of mechanisms [2] including induction or 
enhancement of protein synthesis. Nonionizing EMR may cre-
ate the substrate for enzymatic action OJ' influence binding to 
the substrate. P hotochemical alterations of enzy mes may acti-
vate or deactivate them by a variety of different and sometimes 
precise mechanisms. While short wavelength ultrav iolet radia-
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tion may simply denature the protein, longer wavelength ultra-
violet or visible radiation may cause isomerization or specific 
photochemical changes in a n enzyme which diminish es, en-
ha nces or abolishes its activity . Photochemical conformational 
cha nges may occur before or after the enzyme substrate com-
plex has occurred. Wavelengths as long as 855 nm have been 
found to be effective in markedly enhancing enzyme reaction 
rates [3]. 
Photosensitizers can be used to enhance the selectivity of the 
effect of photons on enzymes, to alter the action spectrum of 
photoinhibition of certain enzymes, or to modify natW'al en-
zyme inhibitors. For instance, if proflavin is reduced by visible 
light in the presence of ascorbic acid, its inhibition of £.'I-chy-
motrypsin is diminished by a factor of 10 [4). In addition, 
enzymes can be chemically modified by the addition of chl'om-
ophoric groups to make the enzyme itself photolabile. For 
example, chymotrypsin is inactivated 5 times more effectively 
by the cis form of p-azophenyldiphenylcarbamylchloride than 
by the trans form. Radiation with 320 nm and 420 nm cha nges 
the ratio of isomers in favor of cis and trans, respectively, and 
therefore degree of inactivation can be r eversibly controlled by 
selection of waveband radiation [5]. Similar systems occur with 
acetylcholinesterase [6,7] and aldolase [8). The enzyme £.'I-chy-
motrypsin can be bound to the cis form of- a modifier which 
eliminates its activity. When exposure to 313 nm radiation 
converts the modifier to the trans form, it falls off the protein 
completely, restoring its activity so that one photon could result 
in 105 molecules of the product of the enzyme reaction in 10 
min [9). 
PERCUTANEOUS RADIATION OF BLOOD 
Considering metabolic need, the skin is highly overperfused. 
Under normal conditions, there is li t tle relationship between 
the quantity of blood vessels and blood in skin and the metab-
olism and function of cutaneous cells. The mean blood flow to 
the skin is 20 to 30 times greater than necessary for physiological 
and metabolic demands of the skin cells and the maximum flow 
may be more than 100 times t he minimum flow (10). This is 
largely because the cutaneous vascular system is a regulator of 
total body temperatW'e. The skin may also be a normal or 
abnormal reservoir for blood. Therefore, because skin blood 
flow primarily serves the organism as a whole, an unusually 
large portion of the blood is available near the body sW'face for 
exposure to nonionizing EMR 
Skin blood flow has been measured by a variety of techniques 
which include h eat exchange kinetics, plethysmography, clear-
ance of inert gases, laser dopIer shift, skin conductance, dye 
studies and radioactive tracers [11-13]. A nude subject at rest 
at an environmental temperature of 35°C has an average cuta-
neous blood flow of 230 to 380 ml per m2 of body sW'face per 
minute [14,15]. This can easily be greatly increased and flow up 
to 1000 ml per m2 per minute has been reported [16]. Flow 
certainly varies from site to site, being greatest in digits, where 
a 600-fold temperature dependent now rate increased capability 
has been reported [17,18], and in the face and perioral areas 
[19]. When flow is accelerated, the skin usually a lso contains 
more blood at anyone time but these 2 pammeters do not 
always run pal'ailel to each other. 
Cutaneous blood flow therefore accounts for about 10% of 
basal cardiac output; as much as 10% of the blood may be in 
the skin during a ny time period. This amoun t can be increased 
significantly by exercise or tol~rable heat load. By changing 
environmental temperatw'e from 28°C to 35°C, skin tempera-
ture rises only 2°C but blood flow increases 3-fold [16]. At rest 
at a mean cutaneous blood flow of about 250 ml/ m2/ min or 500 
ml/min for an adult, an equivalent of the enti.re blood volume 
may pass through the skin 2 or more times dming the time it 
takes to achieve one minimal erythema dose (a bout 20 min) of 
sunlight. With the increased heat load typically present in 
artificial exposure chambers and prolonged expOSUl'es, as much 
as 2 to 10 times the cardiac output may pass through the skin 
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dur ing phototherapy. Much of this blood is exposed to longwave 
ul traviolet, visible and near infrared radiation, more so to t he 
longer wavelengths present due to the optics of skin . 
OPT ICS TARGETING AND THE THERAP EUTIC 
WINDOW 
R adiation of 320-800 nm has proper t ies which make this 
wa veba nd potent ially useful for t he purpose of selective (ther-
apeutic) in vivo photochemistry utilizing exogenously supplied 
chromophore: 
1. This radia tion is not directly very phototoxic: it carries 
s ufficient quantum energy to ini t iate photochemical reactions, 
yet is r ela tively innocuous to exposed human tissues other tha n 
t h e eye. 
Cells are most effi ciently injul"ed directly by radia tion of 
wavelengths shorter t han 320 nm. The photon-induced inflam-
m atory response in skin results from a complex cascade of 
even ts which are poorly understood; the ch.romophores a nd 
molecular mechanisms ar e not known and both may vary with 
th e wavelength (photon energy) of radiation, but DNA is prob-
a bly a primary chromophore and "target" responsible for many 
responses to wavelengt hs shorter than 320 nm. The manifesta-
tion of s kin phototoxicity which has received the most a t tention 
is t he delayed vasodila tion which accompanies inflammation. 
The effectiveness of various portions of the ultraviolet spectrum 
in causing ery thema varies considerably. The exact shape of 
t h e 250-290 nm por tion of the erythema effectiveness curve 
depends on th e time of observation, degree of erythema used as 
endpoin t and other variables. H owever, from 290 to 320 nm the 
sensitivity of skin as measured by the delayed erythema de-
creases by several orders of magnitude. Compared to 290-320 
nm radia tion , wavelengths from 320 to 380 are more t ha n 1,000 
t imes less effective at inducing infla mmation in human skin and 
10,000 times less effective at reducing the viabili ty and func tion 
of huma n peripheral blood lumphocytes. Wavebands beyond 
400 nm have even smaller direct photo toxic potential a nd in 
most cases massive exposure doses or extreme intensit ies would 
cause cutaneous changes related to heat long before biologically 
significant photochemistry would occur. 
P erhaps this situa tion has occurred because we evolved under 
sunlight with maximum irradiance in the 320-800 nm spectral 
r egion. It would not do for a terrestrial a nimal to be extremely 
photosensit ive to this spectral r egion, and tra its such as por-
phyria with destructive endogenous photosensitizers in gpneral 
have clearly been selected against. Whatever the history of 
m an 's general tolerance to this spectral region, th e sit uation 
allows us to supply specific chromophoric molecules and "trig-
ger" them with 320-800 nm radia tion, expecting that within 
wide limits, we can cause responses primarily to the exoge-
nously-provided photochemical pathway of in terest. 
2. This r adiation has photon energy which can cause elec-
t ronic excita tion in many organic molecules a nd can t herefore 
cause selective chemical reactions. 
The minimum activation energy for the formation of break-
a ge of very weak bonds in organic photochemical reactions may 
correspond to photon energies of 1 to 2 ev., i. e., red and near 
infrared radia tion. Thus, wavelengths in the UV, visible and 
near infrared regions can potentially be used for photochem-
otherapy and selective in vivo photochemistry. Photochemical 
reactions differ fTom thermal reactions in several fundamental 
and important ways. Thermal activation of a reaction involves 
collisional excitat ion of vibrational states, whereas photochem -
ical reactions always are init iated by direct electronic excitation 
of a s ingle molecule by a single (or rar ely, 2) photons. Since the 
population of excited vibrational. levels is related to tempera-
ture, a colligative property, a single thermally-driven reaction 
cannot be enhanced by changing temperature without affecting 
all other possible thermal reactions. Furthermore, thermal in-
ertia and regula tory m echanisms in general limit the range of 
temperatures, and rates of t emperatme ch ange that are achiev-
able in vivo. In contrast, use of photons for activation energy to 
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drive a given reaction allows comparatively exquisite con t rol, 
because only certain molecules (c1u-omophores) are excited, the 
excita ti on is to an excited state from which one or more specific 
chemical reactions may occur and fin ally, by varying wave-
length and exposure t ime, the reactions can be readily Con-
trolled without " inertia ." Use of ionizing radiation is less specific 
tha n use of optical r adia tion, because a multiplicity of ionization 
events always occur, and it is impossible to favor a given, 
exogenously-supplied chemical pathway to any great extent. 
3. This radia tion is tr ansmitted into skin and cutan eous 
blood vessels and has an internal dosimetric depth profile; i. e. 
the penetra tion of 320-800 nm radiation into soft t issue is very 
wavelength-dependent because of the optical proper ties of the 
tissue. 
In skin, the major epidermal chl"omophore in this wavelength 
region is melanin, which absorbs shorter wavelengths much 
more strongly than longer wavelength , but has a cont in uous 
absorption spectrum across this entire spectral region. Although 
optical scat tering does occur in the epidermis, it is absorpt ion 
by mela nin that essentially determines the t ransmissio n of 
incident radia tion into a nd through t he epidermis over th e 320-
800 nm region. In the dermis, however, opt ical scattering plays 
a major role in determining the depths to which longwave 
ultraviolet, visible, and near inli'ared radiation penetrates. Der-
mal optical scattering, primarily by collagen fibers, is m u ch 
greater at shor ter wavelengths, such t hat the relative depth of 
penetration of blue visible ligh t into dermis is less t ha n One-
tenth that for red ligh t . In addi t ion, certain often shar p wave-
length bands from 400 to 600 nm are strongly absorbed by the 
blood-borne ciuomophores, hemoglobin and oxyhem oglobin, 
a nd by bilirubin, which is both intravascul ru' a nd extravasculaJ·. 
The precise fate of incident radiation within a person 's s kin 
depends on many individual variables for each layer , bu t it is 
clear Ii'om general models for the op tics of skin that longer 
optical wavelengths penetrate deeper into the t issue. For ex-
ample, whereas 320 nm radia tion is largely attenuated in t he 
first 100 }.tm of t issue, up to 20% of inci<;lent 800 nm radiation 
may be t ransmi tted through t he entire epidermis, dermis, a nd 
subcutaneous adipose layers. In pa rt icular, an "optical window" 
exists over the 600- 1300 nm region, owing ma inly to lack of 
strong absorption by blood and secondarily to lower optical 
scattering wit hin the dermis. Amazingly, on the order of 1 % of 
700- 800 nm radiation can penetrate the en tire human chest 
wall, but less tha n 0.001 % of wavelengths lower than 500 nn) is 
transmitted (JA Parrish : Unpublished data). 
A highly useful advan tage of these optical properties is that 
the wavelength chosen for initiating a particular biologic re-
sponse, r elease of drug, inactivation of enzyme, etc., will largely 
determine which skin layers are affected . With exogenot:tsly 
supplied chromophores having broad action spectra, the depth 
of t issue involvement might be controlled over a wide range. 
The activation or r elease of blood-borne drugs fro m a photola-
bile " package" migh t best be accomplished with wavelengths 
longer tha n 600 nm, or wit h horter wavelengths chosen be-
tween the a bsorption bands of t he hemoglobins. U nder other 
ci.rcumsta nces, it may be advantageous to use 400-420 n m 
radiation because t he very strong Soret absorption ban d of 
oxyhemoglobin could act as an "intravascul ru' sunscreen " to 
protect circulating leukocytes, bu t allow interstitial cells to be 
affected by a given photochemical reaction sequence. 
4. This radiation is absorbed by a variety of molecules a nd 
biomolecules which are nontoxic a nd can therefore be adm in-
istered systemically. 
The chemical structure of molecules will determine th e spe-
cific wavelength of nonionizing electromagnetic radiation that 
will be absorbed. While fully satUTated organic compOUnds 
generally a bsorb wavelengths below 200 nm and unsaturated 
bonds have absorption bands between 200 and 300 nIn, COnju-
gated double-bonds resul t in a bsorption bands between 200 a nd 
400 nm. For larger conjugated molecules, and certain substi-
tuted aJ"omatic compounds, absorption shifts fwther to longer 
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wavelengths; t hese compounds appear colored because of ab-
sorption of various visible wavebands. Although molar extinc-
tion at an absorption spectrum maximum can be proportional 
to the number of conjugated bonds, in biologic macromolecules 
such as proteins or nucleic acids, the absorption maximum is 
not a simple linear sum of the number of conjugated double-
bonds. Absorption characteristics are affected by the addition 
of auxiliary charged side groups and in solution or in vivo 
absorption by compounds containing ionizable groups is pH 
dependent. 
To fu nction as a photosensitizer a molecule must usually be 
capable of more than merely absorbing a photon. In general it 
must be able to be excited by EMR into a long-lived excited 
state, t he triplet state or react to form more long-lived chemi-
cally active species such as free radicals. With certain important 
exceptions, most of the photosensitized reactions in biologic 
systems studied to date involve the participation of molecular 
oxygen. Free dyes are efficient photosensitizers for many bio-
molecules including amino acids, proteins, and nucleic acids. 
Binding of the dye to the substrate, which often precedes 
photooxidation, changes the photosensitizer's efficiency. Acri-
dines, thiazines, xanthenes, anthraquinones, azines, flavin and 
nonmetal containing porphyrins are often efficient photosensi-
tizers of protein degradation. Methylene blue, flavin, psoralens 
and acridines are effective photosensitizers of nucleic acid re-
actions. Unsaturated fatty acid reactions are photosensitized by 
a variety of chemicals including certain porphyrins. 
Clinical photosensitization provides evidence that systemi-
cally administered light absorbing ch emicals can be activated 
in vivo. Hundreds of photosensitizing chemicals of therapeutic, 
industrial, agricultural, or other origin may reach viable skin 
cells via the bloodstream, each having its own pattern of ab-
sorption, metabolism, and binding to skin components. In gen-
eral, these compounds are highly resonant structures with a 
molecular weight of less than 500 and absorb radiation in the 
ultraviolet and visible range. Some of the more common com-
pounds include tetracyclines, especially demethylchlortetracyc-
line, sulfonamides, especially sulfanilamide, griseofulvin, phe-
nothiazines, especially chlorpromazine, thiazides, psoralens, sul-
fony lureas, and many others. Many are triheterocyclic com-
pounds and most are fluorescent although flu orescence as such 
is not often correlated with photosensitizing effectiveness. 
PHOTON DEPENDENT DRUG DELIVERY SYSTEMS 
A potentially useful treatment system is a photon-activated 
drug delivery system (PADDS). The most direct PADDS would 
use photons to modify drugs in vivo in the same ways enzymes 
can be modified. P hotochemically directed synthetic chemistry 
and the expertise and techniques developed for photoaffinity 
labeling could be utilized to design a variety of drugs for local 
activation or deactivation in specific tissue sites and depths 
after systemic administration. Binding, release, biotransforma-
tion and inhibition could be influenced by chromophoric pros-
thetic groups which could be photoisomerized, cleaved, or re-
moved by specific wavebands of 320 to 800 nm radiation. Here 
lies an exciting challenge to the photo biochemist. 
Another example of .P ADDS is t he use of photolabile lipo-
somes to deliver medications. Liposomes are ordered concentric 
closed membrane vesicles composed of phospholipid bilayers in 
aqueous suspension and enclosing an aqueous phase [20]. Be-
cause they are useful models for biological m embranes, lipo-
somes have been extensively studied [21-24] and their potential 
as drug carriers [25,26] has been recognized and t issue targeting 
has been examined. A variety of drugs can be trapped inside of 
liposomes whose properties of "leakiness," tissue dis tribution, 
stability and half-life can be markedly influenced by their lipid 
c'ontent and technique of preparation. For example, the addition 
of cholesterol results in decrease "leakiness" and sphinogmyelin 
confers resistance to the recognized disruptive effects of serum 
[27]. Cationic lipids or anionic polar lipids increase the volume 
of the aqueous phase within the liposome. A variety of prepa-
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ration maneuvers result in small unilamellar vesicles (20-50 
mm) , large unilamellar vesicles (up to 100 nm diameter) [28] or 
multilamellar vesicles. Extrusion through polycarbonate mem-
branes can be used to sterilize and standardize the size of th e 
vesicles. Half-times for in vivo biodegradation or destruction of 
vesicles can be varied from 12 to 600 hours depending upon 
their composition [29]. 
Natural targeting to the reticuloendothelial system occurs 
but to som e extent one can target liposomes by varying size 
and charge and route of administration [22] to increase distri-
bution to specific organs such as liver, spleen or lung. Liposomes 
have been targeted to lung, nodes, liver, and spleen after intra-
venous administration, to nodes and skin after subcutaneous 
injection and have also been given intraarticularly [30] and 
intratracheally [31]. Liposomes have also been targeted to 
specific tissue sites by covalent binding of liposomes to anti-
bodies to specific tissue antigens [32]. 
Heat has been used to cause in vivo release of drug from 
systemically administered liposomes [33]. MixtUl'es of dipalym-
itoyl and disteroyl phosophtidylcholine have a transition tem-
perature slightly above body temperature, and at temperatures 
above transition temperature the liposomes rapidly become 
leaky. Elevated methotrexate levels were achieved in murine 
skin tumors heated to 42°C after intravenous injection of th e 
drug entrapped in liposomes. The heat-induced disruption of 
liposomes intravascularly resulted in local accumulation of 
methotrexate in the tissue. Temperature dependent liposome 
drug delivery has some inherent restriction of lipid composition 
because addition of those lipids known to stabilize liposomes in 
serum may also alter the transition temperature. 
Pure lipid liposomes can be disrupted by photosensitizers and 
EMR of appropriate wavelength. Toluidine blue and visible 
light of wavelengths longer than 520 nm causes lysis of lipo-
somes as measured by glucose leakage or a change in ligh t 
scattering. Before rupture occw'S the membrane lipids undergo 
peroxidative damage which can be prevented by carotenoids 
[34,35]. Chlorpromazine and long-wave ultraviolet radiation 
causes oxygen dependent damage to liposomes and release of 
trapped spin la bel marker [36]. Exposures of retinal enriched 
liposomes to 365 nm radiation induces sensitized oxidation of 
the lipid bilayer and increased fluidity detected by spin label 
technique. This in turn leads to lysis of the liposome and release 
of entrapped chromate ions [37]. 
By adding photosensitized release m echanisms to the known 
techniques for liposome targeting it may be possible to selec-
tively treat diseases of skin or localized tissue abnormalities. 
There are several photosensitizers known to cause membrane 
damage including xanthene dyes, thiazine dyes, porphyrins, 
chlorpromazine and others, which could be used to photosen-
sitize liposomes to a specific wavelength of EMR which could 
then be used to alter the liposome membrane and release drugs 
from the liposomes in vivo. This would add to the ability to 
target dr ugs to specific anatomic sites (exposed sites) and t issue 
depths (dependent on wavelengths). Certain medications could 
be protected from biotransformation until released locally by 
EMR or rate of drug release could be increased or decreased by 
irradiation. Drug-bearing, light-sensit ive liposomes could be a 
depot from which light could trigger periodic partial release to 
obtain intermittent 01' partial dr ug action or total release to 
termjnate the action. A second photosensitizer could be released 
by the action of the fIrst and subsequently utilized for photo-
chemotherapy by radiation with a second waveband (P ADDS-
photochemotherapy) . . 
Photosensitizers could be bound to the liposomes, incorpo-
rated into the membrane 01' entrapped within medicine-con-
taining liposomes. The bilayer membrane would transmit the 
radiation absorbed by most photosensitizers. Membrane fusion 
could be used to join photosensitized-containing liposomes to 
drug-containing iiposomes or to join liposomes to cell walls. 
Lipophilic photoactivatable reagents are used to identify lipid-
embedded domains in membranes [38]. Compounds that fIrst 
July 1981 
dissolve in lipid bilayers and can subsequently be photoacti-
vated have been developed [39-43). Fatty acids containing 
photoactivatable groups have been synthesized [44-46] and 
these could be incorporated into the photolipids used to produce 
liposomes. This synthetic chemistry and photochemistry exper-
tise may be utilized to produce nontoxic, light sensitive lipo-
somes. Another challenge for the chemists. 
MANIPULATION OF EXPOSURE VARIABLES 
The precision, efficacy, and safety of all forms of therapeutic 
photomedicine can be enhanced by a variety of manipulations 
of the exposure source. The spectral power distribution can be 
selected to match the action spectrum of desired therapeutic 
results, to obtain verified waveband interactions, and to mini-
mize side effects. Intensity can also be varied to give a desig-
nated dose over different periods of time. Shorter exposures 
may be more convenient, longer exposure may permit exposure 
of more blood flowing through the skin. 
If one tissue response is related only to total dose and a 
second response is related to intensity as well, it may be possible 
to select one of the responses by varying the intensity while 
achieving the same total dose. For instance, the presence and 
degree of the delayed erythema component of ultraviolet-in-
duced inflammation are dependent on exposure dose. For a 
given area, the exposure dose equals the produce of i.rradiance 
and exposure time. Within extremely wide limits (>lOlO-fold 
range) [47] delayed erythema response is independent of ina-
diance ("dose rate"); that is, the influence of doubling the 
irradiance may be compensated for by halving of the exposure 
time (48) . However, not all photochemically initiated biologic 
responses necessarily follow this "reciprocity law." For example, 
reciprocity over a wide range of irradiances is not the case for 
thermally induced photobiologic responses. As a site is exposed, 
heat transfer away from the exposure area occurs until at some 
equilibrium, the temperature attained at the exposw'e site and 
certain related respon$es such as immediate vasodilitation are 
proportional to the irradiance, and not the exposure dose. It 
may, therefore, be possible to select for certain competing 
photobiological or thermal responses in the host by varying 
intensity. Lasers may be very useful in this regard. 
Additional advantages can be gained by altering not only the 
exposure conditions but also by altering the host. The sensitiv-
ity of skin to specific EMR wavebands can be decreased or 
increased by the topical application of a variety of chemicals. If 
absorbing or scattering compounds are applied to the skin, 
sensitivity to radiation in the spectral regions involved will 
decrease. On the other hand, aqueous media applied to normal 
Caucasian skin results in the extraction of UV -absorbing com-
pounds from the skin, causing a corresponding increase in 
transmittance of the stratum corneum as appropriately mea-
sured in vitro, and an increase in sensitivity to ultraviolet 
radiation in vivo [49,50). 
Other alterations of optical properties of skin are possible. 
Normal skin has a single, continuous though somewhat irregu-
lar ai.r-tissue interface in which the refractive index (no) changes 
from that of air, 1.0, to that of stratum corneum (1.55) [51). 
This causes a regular reflectance of 5% to 7% across the UV, 
visible, and near-infrared spectra [52]. Adding a layer of clear, 
lipophilic liquid such as mineral oil, which readily spreads over 
the surface of skin, and has a refractive index (nD = 1.48) 
between that of air and stratum corneum, does little to reduce 
regular reflectance occurring at the optical interface with air. 
However, in abnormal tissue such as psoriasis, there are mul-
tiple air-tissue interfaces along the path of incident radiation as 
it enters the stratum corneum and regular reflectance occurs at 
each such interface. As a result the total regula]" reflectance is 
considerably greater than for the single air-tissue interface seen 
in normal skin. When mineral oil is applied to the scaly plaques 
typical of psoriasis vulgaris, it appru'ently fills air spaces be-
tween superficial flakes of corneocytes. Regulru' reflectance of 
the plaque is thereby decreased because the oil provides a much 
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better match of refractive index between the flakes of cornea-
cytes than does air [53). Reducing regular reflectance in this 
manner must necessarily increase the fraction of incident radia-
tion transmitted into the abnormal tissue. This is one example 
of selective increase in EMR transmission. 
It is also possible to change skin temperature by applying 
conductive or radiative heat. This would alter the percutaneous 
and tissue clearance of certain photosensitizers or medications 
and also influence cutaneous blood flow. Blood flow can also be 
increased locally by pharmacological agents, by suction or by 
prior exposure to more erythemogenic shorter wavelength ul-
traviolet radiation (250-300 nm). Vessel permeability can be 
altered pharmacologically to release more photosensitizers or 
medication into tissue. Selective protectors or quenchers could 
also be given systemically or locally released in order to spare 
the host from certain known side effects. All of these changes 
may be combined to deliver more drug bearing liposomes, 
blood-borne photosensitizers, or medications to t he heated tis-
sues or to skin. 
The manipulation of anyone of these exposure dose param-
eters may have only small influence on treatment efficacy or 
side effects but their combined effect could make therapeutic 
photomedicine a safer and more useful modality and a chal-
lenging science. 
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